Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Prasugrel Disappoints in PIII Study for Ischemic Cerebrovascular Disease
October 24, 2016
- 295 Staffers Applied for Voluntary Redundancy: Sumitomo Dainippon
October 24, 2016
- Daiichi Sankyo Stops Patient Enrollment for Pexidartinib PIII, but Continues Study
October 24, 2016
- Oncolys, DNA Chip Research Team Up to Study Potential of TelomeScan as Companion Diagnostic for CRPC
October 24, 2016
- Kipres Generics Might Add Bronchial Asthma Indication before December Listing
October 21, 2016
- Janssen Files Anti-IL-6 Antibody Sirukumab for RA
October 21, 2016
- Humira Biosimilar Hits Primary Endpoint in Global PIII: Fujifilm, Kyowa Kirin
October 20, 2016
- Kaketsuken’s Biz Transfer Talks Fall Apart, but Minister Nixes Its Continued Operations
October 20, 2016
- Astellas Calls Off Biz Transfer Talks with Kaketsuken
October 19, 2016
- UK’s Clinigen Launches Japan Operations with Takeover of Foscavir
October 19, 2016
- Kaketsuken Denies Unauthorized Manufacturing or Cover-up, Blames Ambiguity in Approval Doc
October 19, 2016
- Entyvio’s Real-World Data Support Trial Results: Takeda
October 18, 2016
- Ethical Drug Sales Up 2.7% in August: Crecon Report
October 18, 2016
- JT Grants S. Korea Rights for Anemia Drug to JW Pharmaceutical
October 17, 2016
- PDUFA Date for COPD Drug Set for May 29, 2017: Sunovion
October 17, 2016
- Sandoz Will Outpace Generic Market Growth: New Japan Chief
October 14, 2016
- Gilead Japan Trying to Dig Up Untreated Hep C Patients as Demand Ebbs
October 14, 2016
- Mark Tennyson to Take Helm of Amgen Astellas BioPharma
October 14, 2016
- Daiichi Sankyo, Dana-Farber Link Up on Lung Cancer Preclinical Research
October 14, 2016
- Gilead Japan Eyes Cancer, Inflammatory Disease Meds to Raise Profile as Specialty Pharma
October 13, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…